Intrexon Co. (NYSE:XON) was the target of some unusual options trading on Tuesday. Stock investors acquired 11,979 call options on the company. This represents an increase of Infinity compared to the average daily volume of 0 call options.
In other news, Director Robert B. Shapiro purchased 2,850 shares of the stock in a transaction dated Tuesday, August 22nd. The stock was acquired at an average cost of $17.50 per share, for a total transaction of $49,875.00. Following the acquisition, the director now owns 43,157 shares of the company’s stock, valued at $755,247.50. The acquisition was disclosed in a filing with the SEC, which is available at this link. 55.10% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Synovus Financial Corp grew its stake in Intrexon by 0.6% during the 2nd quarter. Synovus Financial Corp now owns 33,613 shares of the biotechnology company’s stock worth $810,000 after buying an additional 200 shares during the last quarter. Alliancebernstein L.P. grew its stake in Intrexon by 0.6% during the 2nd quarter. Alliancebernstein L.P. now owns 32,610 shares of the biotechnology company’s stock worth $786,000 after buying an additional 200 shares during the last quarter. Legal & General Group Plc grew its stake in Intrexon by 2.1% during the 2nd quarter. Legal & General Group Plc now owns 18,843 shares of the biotechnology company’s stock worth $454,000 after buying an additional 393 shares during the last quarter. CWM LLC grew its stake in Intrexon by 1.7% during the 2nd quarter. CWM LLC now owns 36,143 shares of the biotechnology company’s stock worth $871,000 after buying an additional 597 shares during the last quarter. Finally, National Planning Corp grew its stake in Intrexon by 13.4% during the 2nd quarter. National Planning Corp now owns 12,958 shares of the biotechnology company’s stock worth $316,000 after buying an additional 1,528 shares during the last quarter. Hedge funds and other institutional investors own 77.28% of the company’s stock.
Intrexon (NYSE XON) opened at $12.85 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.05 and a quick ratio of 1.85. Intrexon has a 52 week low of $10.26 and a 52 week high of $31.85.
XON has been the subject of a number of research analyst reports. BidaskClub downgraded Intrexon from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Northland Securities set a $30.00 price target on Intrexon and gave the company a “buy” rating in a report on Monday, August 7th. JMP Securities reiterated an “outperform” rating and issued a $42.00 price target on shares of Intrexon in a report on Thursday, October 5th. Griffin Securities reiterated a “buy” rating and issued a $55.00 price target on shares of Intrexon in a report on Friday, October 6th. Finally, Zacks Investment Research downgraded Intrexon from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. Intrexon presently has an average rating of “Hold” and a consensus price target of $38.50.
WARNING: This piece was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://stocknewstimes.com/2017/11/19/intrexon-sees-unusually-large-options-volume-xon.html.
Intrexon Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Co. and related companies with MarketBeat.com's FREE daily email newsletter.